Beauchamp EM, Leventhal M, Bernard E, et al. is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. Blood Cancer Discov. 2021;2(5):500-517. doi:10.1158/2643-3230.BCD-20-0224.

Ghosh S, Raundhal M, Myers SA, et al. Identification of RIOK2 as a master regulator of human blood cell development. Nat Immunol. 2022;23(1):109-121. doi:10.1038/s41590-021-01079-w.

Fink EC, McConkey M, Adams DN, et al. is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018;132(14):1535-1544. doi:10.1182/blood-2018-05-852798.

Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2):e35. doi:10.1371/journal.pmed.0050035.

Jaiswal S, Ebert BL. MDS is a stem cell disorder after all. Cancer Cell. 2014;25(6):713-4. doi:10.1016/j.ccr.2014.06.001.

Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691-8. doi:10.1200/JCO.2013.52.3381.

Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-12. doi:10.1182/blood-2014-06-582809.

Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509-20. doi:10.1016/j.ccr.2014.08.001.

Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523(7559):183-8. doi:10.1038/nature14610.

Guirguis AA, Ebert BL. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr Opin Cell Biol. 2015;37:61-7. doi:10.1016/j.ceb.2015.10.004.